RPRX: The Best-In-Class Machine On A Temporary Lease

# RPRX: The Best-In-Class Machine On A Temporary Lease

Let's get the obvious thing out of the way: Royalty Pharma is one of the most expensive businesses you'll ever own at a cheap multiple.

It ran $674 million in Q2 revenue, up 16.5% year over year, at a 62% operating margin. Gross margin sits at 99.8%. It deploys roughly $3 billion of annualized operating cash flow, funds a dividend compounding at 24% a year, and spends 5.5% to 6.5% of portfolio receipts on overhead. That is not a company. That is a tollbooth with a biopharma license plate.

And you can buy it for a forward P/E near 10. Not 10 on a one-time windfall. On a forward EPS of $5.34 this year and $5.73 in 2027. Somewhere around here, the market keeps convincing itself it found a pricing error.

Now the honest part.

The stock closed at about $57.16 on October 2, and it is not quietly grinding higher. It punched through the $63–64 zone earlier this year, lost the bid, and has been drifting lower. It sits below both its 20-day and 50-day averages. RSI is hovering in the mid-30s, which is "getting a little nervous" territory, not "capitulation." Momentum over the past month is negative by double digits. This is a healthy pullback inside a healthy uptrend — the kind that feels terrible while it's happening and obvious in hindsight.

So what is the actual read? Buy the weakness, don't chase the current level. The machine is not broken. The tape just told you to wait for a better price.

Here is why I say that with conviction, and where I'd actually be wrong.

The bull case is real, not rhetorical.

This is not a story stock propped up by a roadmap deck. Q2 guidance went up a second time this year — Portfolio Receipts now pointed at $3.4 to $3.5 billion — and Royalty Receipts grew 14%, carried by real assets: Tremfya, Voranigo, Imdelltra, Evrysdi. Ziihera cleared FDA back in late August, opening a genuine new oncology royalty stream that won't even show up until the November print. Analysts — Citi, Goldman, Morgan Stanley — all raised targets, into the $65 to $70 zone, and kept their positive ratings.

Royty Pharma also does the thing most pharma investors never learn to appreciate: it buys the downside out of its own deals. When Novartis' pelacarsen Phase 3 blew up the primary endpoint in September, RPRX had structurally coupled that royalty to the "stable and predictable" Spinraza cash flow. No further pelacarsen milestone payments owed. Management still expects a positive return. That is not luck. That is the entire business model working exactly as designed.

The bear case is real too, and it's not a strawman.

The leverage. $8.96 billion in debt against $837 million in cash as of end-June. A D/E around 1.31 and roughly $350 to $360 million of expected annual interest. In a rising-rate world, that is not a footnote — it's the central risk on the balance sheet, and it's why the multiples never compress the way the cash flow arguably deserves.

Then there's the slow erosion. Promacta royalties fell 75% to $8 million in Q2 as generics chewed through it. Imbruvica payments dropped 16% to $36 million. These are legacy assets paying down; the replacement pipeline is doing its job, but patent cliffs don't care how good the last quarter was. And RPRX keeps issuing shares to fund its expansion, which is exactly why the market-cap number on this stock is a minefield — $33 billion if you count all shares, closer to $22–25 billion if you count only the publicly traded Class A stock. Dual-class structure. Same company, three different sizes depending on who's counting.

And yes, the rusfertide bet — the $100 million Zealand deal for a polycythemia vera royalty — carries a ceiling. The 1% global sales royalty shrinks to 0.75% once sales clear $1.5 billion. It's a meaningful therapy, but it is not an infinite money printer. Even the FDA decision date that was floating around for Q3 has effectively closed by now, and nobody's reporting the outcome.

Where that leaves us.

I'd rather own this business at $44–$45 than pay up near $63. The internals — margins, cash flow, capital allocation, downside-protected deal structuring — are best-in-class. The technicals say buyers should be impatient on dips and patient on rallies, because the near-term tape still favors the seller. The leverage and patent erosion are not problems you solve with a positive attitude; they're the reason this stock trades below its pharma peers even while blowing them out on returns on capital.

There are systematic forecast bands floating around that want to tell you RPRX reverts to the low-$40s and possibly lower. Treat them as noise. On this name, their track record has been mediocre at best — the model has been wrong far more often than it's been right. I'm not going to build a thesis on a line drawn by a spreadsheet.

My actual thesis is simpler and more boring: this is a compounder you can accumulate on weakness, not a stock to chase after a failed breakout. The downside is cushioned — beta of 0.41, and a balance sheet that, leveraged as it is, still holds $19.8 billion in assets. The upside is a forward multiple that keeps implying the market thinks the royalty machine will somehow stall.

Nothing in the Q2 print suggests it will.

So here's the move: let the stock come to you. Add into the $54 support shelf and the low-$50s with conviction, keep adding toward $50 if the tape keeps testing it, and stop chasing until it reclaims $60. The deal hasn't changed. Only the price has. And in this business, price is the only thing you actually control.